| Literature DB >> 32802507 |
Ping Yang1, Junjie Liu2, Tianci Yang3, Lei Zhang4, Peiyou Gong5, Boqing Li2, Xiuzhi Zhou2.
Abstract
BACKGROUND: Helicobacter pylori (H. pylori) is a common human pathogen, which is closely correlated with gastric cancer (GC). However, the mechanism of H. pylori-related GC has not been elucidated. This study aimed to explore the role of H. pylori infection in GC and find biomarkers for early diagnosis of H. pylori-related GC.Entities:
Year: 2020 PMID: 32802507 PMCID: PMC7410007 DOI: 10.1155/2020/6285987
Source DB: PubMed Journal: Biochem Res Int
Summary of clinical information of 69 patients.
| Characteristics | Patients ( |
|---|---|
| Age (year) | |
| ≤60 | 31 |
| >60 | 38 |
| Sex | |
| Male | 46 |
| Female | 23 |
| Histopathological type | |
| Gastritis | 32 |
| Gastric adenocarcinoma | 37 |
|
| |
| Negative | 18 |
| Positive | 51 |
Differential expression of miRNAs of H. pylori-negative and -positive patients.
| miRNA ID | LogFC |
|
|
| Adj. | Expression |
|---|---|---|---|---|---|---|
| hsa-miR-455 | −1.29961 | −13.2889 | 14.50158 | 1.32 | 6.20 | Down |
| hsa-miR-223 | 2.015725 | 7.995567 | 7.036115 | 2.91 | 5.02 | Up |
| hsa-miR-200a-5p | −1.04839 | −7.29849 | 5.792449 | 1.02 | 9.54 | Down |
| hsa-miR-146b | 1.846493 | 7.098055 | 5.422075 | 1.47 | 0.000115 | Up |
| hsa-miR-200a-3p | −1.18346 | −6.46158 | 4.208209 | 4.97 | 0.000249 | Down |
| hsa-miR-155 | 1.41517 | 6.230643 | 3.753807 | 7.83 | 0.000335 | Up |
| hsa-miR-411 | −1.54782 | −5.84129 | 2.971589 | 1.71 | 0.00062 | Down |
| hsa-miR-551b | −1.30788 | −5.44908 | 2.164424 | 3.85 | 0.000994 | Down |
| hsa-miR-142-3p | 1.67688 | 5.430155 | 2.12503 | 4.00 | 0.000994 | Up |
| hsa-miR-203 | −1.63669 | −5.12951 | 1.494025 | 7.54 | 0.001476 | Down |
| hsa-miR-142-5p | 1.677953 | 5.051426 | 1.32866 | 8.90 | 0.001609 | Up |
| hsa-miR-153 | −1.47449 | −4.88801 | 0.980864 | 0.000126 | 0.002045 | Down |
| hsa-miR-204 | −1.55239 | −4.24223 | −0.41065 | 0.000513 | 0.006184 | Down |
| hsa-miR-196b | 1.594266 | 3.80117 | −1.36658 | 0.001355 | 0.012736 | Up |
| hsa-miR-509 | 1.069763 | 3.765869 | −1.44288 | 0.001465 | 0.013238 | Up |
| hsa-miR-326 | −1.20269 | −3.53852 | −1.93239 | 0.002417 | 0.019915 | Down |
| hsa-miR-146a | 1.324456 | 3.446357 | −2.1296 | 0.00296 | 0.022082 | Up |
| hsa-miR-299-5p | −1.04861 | −3.32334 | −2.39132 | 0.003877 | 0.027607 | Down |
| hsa-miR-520e | 1.32247 | 3.302749 | −2.43493 | 0.004055 | 0.028448 | Up |
| hsa-miR-650 | 1.709805 | 3.294791 | −2.45177 | 0.004127 | 0.028522 | Up |
| hsa-miR-138 | 1.114925 | 3.195115 | −2.6619 | 0.00513 | 0.033381 | Up |
| hsa-miR-368 | −1.02603 | −3.19023 | −2.67214 | 0.005185 | 0.033381 | Down |
Figure 1Identification of DEMs and DEGs between H. pylori-negative and -positive patients from GEO. Heat map (a) and volcano map (c) for DEGs between H. pylori-negative (Hp−) and -positive (Hp+) groups from GSE27411. Heat map (b) and volcano map (d) for DEMs from GSE19769. Red and green colors indicate significant gene overexpression and underexpression, respectively.
Figure 2The miRNA-mRNA coexpression network. The diamonds represent aberrant miRNAs, and the circles represent overlapped genes. The red nodes indicate upregulated genes, and the blue indicate downregulated genes. Lines represent an interaction between two genes.
Top 10 GO functions of the cross-genes in the network.
| Category | Gene terms | Count |
|
|---|---|---|---|
| Biological process | GO:0003148, outflow tract septum morphogenesis | 10 | 1.24 |
| GO:0003151, outflow tract morphogenesis | 15 | 3.98 | |
| GO:0001655, urogenital system development | 30 | 6.76 | |
| GO:0003279, cardiac septum development | 17 | 1.22 | |
| GO:0060411, cardiac septum morphogenesis | 13 | 1.60 | |
| GO:0010632, regulation of epithelial cell migration | 26 | 1.74 | |
| GO:0010631, epithelial cell migration | 29 | 1.75 | |
| GO:0061564, axon development | 33 | 1.77 | |
| GO:0043542, endothelial cell migration | 25 | 1.77 | |
| GO:0090132, epithelium migration | 29 | 2.09 | |
|
| |||
| Cellular component | GO:0005667, transcription factor complex | 23 | 4.28 |
| GO:0097060, synaptic membrane | 26 | 9.71 | |
| GO:0045211, postsynaptic membrane | 21 | 2.70 | |
| GO:0099699, integral component of synaptic membrane | 14 | 3.31 | |
| GO:0005912, adherens junction | 28 | 7.12 | |
| GO:0099240, intrinsic component of synaptic membrane | 14 | 7.62 | |
| GO:0033267, axon part | 22 | 0.000108619 | |
| GO:0000790, nuclear chromatin | 20 | 0.000128584 | |
| GO:0099055, integral component of postsynaptic membrane | 11 | 0.000162968 | |
| GO:0000151, ubiquitin ligase complex | 16 | 0.000198327 | |
|
| |||
| Molecular function | GO:0000978, RNA polymerase II proximal promoter sequence-specific DNA binding | 38 | 5.75 |
| GO:0000987, proximal promoter sequence-specific DNA binding | 39 | 5.92 | |
| GO:0035326, enhancer binding | 19 | 1.24 | |
| GO:0000980, RNA polymerase II distal enhancer sequence-specific DNA binding | 15 | 1.89 | |
| GO:0001158 enhancer sequence-specific DNA binding | 16 | 5.18 | |
| GO:0003682, chromatin binding | 34 | 9.92 | |
| GO:0001228, DNA-binding transcription activator activity, RNA polymerase II-specific | 29 | 2.20 | |
| GO:0004714, transmembrane receptor protein tyrosine kinase activity | 9 | 7.94 | |
| GO:0003712, transcription coregulator activity | 32 | 1.19 | |
| GO:0019199, transmembrane receptor protein kinase activity | 10 | 1.30 | |
Top 10 KEGG pathways of the cross-genes in the network.
| KEGG terms | Count |
|
|---|---|---|
| MAPK signaling pathway | 25 | 3.70 |
| Axon guidance | 17 | 3.89 |
| Ras signaling pathway | 19 | 9.06 |
| TGF-beta signaling pathway | 11 | 0.000134809 |
| cGMP-PKG signaling pathway | 15 | 0.000184067 |
| Human cytomegalovirus infection | 18 | 0.000186779 |
| Adrenergic signaling in cardiomyocytes | 14 | 0.00018806 |
| Hepatocellular carcinoma | 15 | 0.000196653 |
| Rap1 signaling pathway | 17 | 0.000244921 |
| ErbB signaling pathway | 10 | 0.000259955 |
| Growth hormone synthesis, secretion, and action | 12 | 0.000281056 |
Figure 3Prognostic value of hub genes for GC patients from TCGA. Overall survival time of GC patients with over- or underexpression of (a) CALML4, (b) PITX2, (c) hsa-miR-196b-3p, (d) SMAD6, (e) TGFB2, and (f) hsa-miR-196b-5p. CALML4: calmodulin-like protein 4; PITX2: paired-like homeodomain 2; SMAD6: SMAD family member 6; TGFB2: transforming growth factor beta 2.
Figure 4Validation of miRNA and cross-gene expression. (a) Representative immunohistochemical results of CALML4, SMAD6, PITX2, and TGFB2. (b) IHC staining positive rate of CALML4, SMAD6, PITX2, and TGFB2. (c) The expression of hsa-miR-196b-3p and hsa-miR-196b-5p from TCGA database. (d) The expression of hsa-miR-196b-3p and hsa-miR-196b-5p in 69 patients with or without H. pylori infection, and the expression level of (e) hsa-miR-196-3p, not (f) hsa-miR-196-3p, in patients with H. pylori infection was significantly higher. All tests were independently manipulated at least 3 times, with the conversion of gene expression value to log2 (fold change).